By Ramsey Baghdadi
In February, during a Congressional hearing focusing on the Food & Drug Administration’s approval of Sanofi-Aventis ’ antibiotic Ketek, a...
FDA's Temple of Wisdom: The Dean of Drug Development
FDA will have new money and new authority before the year is out. But translating the new drug safety reforms into practice will be the responsibility of some old hands, including the Robert Temple, the dean of FDA's drug review group. The question drug companies should have: What is he thinking?